Literature DB >> 10837553

Adeno-associated virus as a gene delivery system.

.   

Abstract

Adeno-associated virus (AAV) has several characteristics which make it extremely attractive as a gene transfer vector: (1) no known pathogenicity; (2) high efficiency and the ability to remain latent; (3) a minimal number of antigens ensuring minimal immunogenicity; (4) the ability to transduce post-mitotic cells; (5) possible advantages of site-specific integration; and (6) a broad host and cell range. The human isolate, AAV-2, is the best studied and has been the focus for gene delivery experiments. This review will discuss recent in vivo experiments demonstrating the utility of AAV in animal models of neurodegenerative disease.

Entities:  

Year:  1997        PMID: 10837553     DOI: 10.1016/s0169-409x(97)00024-0

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  11 in total

1.  Targeted vault nanoparticles engineered with an endosomolytic peptide deliver biomolecules to the cytoplasm.

Authors:  Muri Han; Valerie A Kickhoefer; Glen R Nemerow; Leonard H Rome
Journal:  ACS Nano       Date:  2011-07-26       Impact factor: 15.881

2.  Nanotherapy silencing the interleukin-8 gene produces regression of prostate cancer by inhibition of angiogenesis.

Authors:  Ravikumar Aalinkeel; Bindukumar Nair; Chih-Kuang Chen; Supriya D Mahajan; Jessica L Reynolds; Hanguang Zhang; Haotian Sun; Donald E Sykes; Kailash C Chadha; Steven G Turowski; Katelyn D Bothwell; Mukund Seshadri; Chong Cheng; Stanley A Schwartz
Journal:  Immunology       Date:  2016-08       Impact factor: 7.397

3.  Oral vaccination with adeno-associated virus vectors expressing the Neu oncogene inhibits the growth of murine breast cancer.

Authors:  Jason C Steel; Giovanni Di Pasquale; Charmaine A Ramlogan; Vyomesh Patel; John A Chiorini; John C Morris
Journal:  Mol Ther       Date:  2013-01-08       Impact factor: 11.454

4.  Gene-directed enzyme prodrug therapy for localized chemotherapeutics in allograft and xenograft tumor models.

Authors:  K H Carruthers; G Metzger; M J During; A Muravlev; C Wang; E Kocak
Journal:  Cancer Gene Ther       Date:  2014-09-19       Impact factor: 5.987

5.  Acid-degradable cationic dextran particles for the delivery of siRNA therapeutics.

Authors:  Jessica L Cohen; Stephanie Schubert; Peter R Wich; Lina Cui; Joel A Cohen; Justin L Mynar; Jean M J Fréchet
Journal:  Bioconjug Chem       Date:  2011-05-24       Impact factor: 4.774

6.  Fat grafting as a vehicle for the delivery of recombinant adenoassociated viral vectors to achieve gene modification of muscle flaps.

Authors:  Katherine H Carruthers; Matthew J During; Alexander Muravlev; Chuansong Wang; Ergun Kocak
Journal:  Ann Plast Surg       Date:  2013-06       Impact factor: 1.539

7.  A comparative study of primary and recurrent human glioblastoma multiforme using the small animal imaging and molecular expressive profiles.

Authors:  Liang-Ting Lin; Shih-Hwa Chiou; Te-Wei Lee; Ren-Shyan Liu; Jeng-Jong Hwang; Chih-Hsien Chang; Hsin-I Ma; Yi-Jang Lee
Journal:  Mol Imaging Biol       Date:  2013-06       Impact factor: 3.488

8.  Well-defined degradable cationic polylactide as nanocarrier for the delivery of siRNA to silence angiogenesis in prostate cancer.

Authors:  Chih-Kuang Chen; Wing-Cheung Law; Ravikumar Aalinkeel; Bindukumar Nair; Atcha Kopwitthaya; Supriya D Mahajan; Jessica L Reynolds; Jiong Zou; Stanley A Schwartz; Paras N Prasad; Chong Cheng
Journal:  Adv Healthc Mater       Date:  2012-07-26       Impact factor: 9.933

9.  A Therapeutic Role for Survivin in Mitigating the Harmful Effects of Ionizing Radiation.

Authors:  Katherine H Carruthers; Gregory Metzger; Eugene Choi; Matthew J During; Ergun Kocak
Journal:  Sarcoma       Date:  2016-04-17

Review 10.  In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease.

Authors:  Cia-Hin Lau; Yousin Suh
Journal:  F1000Res       Date:  2017-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.